A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study Of Nivolumabversus Placebo In Combination With Neoadjuvant Chemotherapy And Adjuvant Endocrine Therapy In Patients With High-Risk, Estrogen Receptor-Positive (ER+), Human Epidermalgrowth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer Read more
Phase III Randomized Adjuvant Study Of Pembrolizumab In Muscle Invasive And Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation Read more
Phase II Study Of Front Line Therapy With Nivolumab And Salvage Nivolumab + Ipilimumab In Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260 Read more
A Phase 2 Study Of Cabozantinib In Combination With Atezolizumab As Neoadjuvant Treatment For Muscle-Invasive Bladder Cancer (ABATE) Read more
A Phase II Clinical Trial To Study The Efficacy And Safety Of Pembrolizumab (MK-3475) In Subjects With High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive To Bacillus Calmette-Guerin (BCG) Therapy Read more
Phase Ib/II Trial Of Pembrolizumab (MK-3475) Combination Therapies In Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Read more
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Study The Efficacy And Safety Of Pembrolizumab (MK-3475) In Combination With Chemoradiotherapy (CRT) Versus CRT Alone In Participants With Muscle-Invasive Bladder Cancer (MIBC) (KEYNOTE-992) Read more
A Phase Ib/Ii,Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-Tnbc) Read more
